Facebook Instagram X-twitter Linkedin

CJC-1295 Without DAC 5mg + IPA 5mg (10mg)

Table of Contents

  • Quickstart Highlights

CJC-1295 (without DAC) + Ipamorelin (10mg) protocols center on this synergistic growth hormone–releasing peptide (GHRP + GHRH analog) combination designed to stimulate natural growth hormone (GH) pulses. CJC-1295 (no DAC) promotes GH release via the pituitary, while Ipamorelin enhances pulsatile secretion without significantly affecting cortisol or prolactin. Together, they may support recovery, fat metabolism, sleep quality, and lean muscle development. This guide outlines a subcutaneous administration approach optimized for the combined 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL total concentration (2.5 mg/mL each compound)
  • Typical daily range: 200–300 mcg per dose, 1–3 times daily (subcutaneous)
  • Easy measuring: At 5 mg/mL total, 1 unit = 0.01 mL = 50 mcg combined peptides on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support natural GH secretion, recovery, fat loss, and muscle growth
  • Schedule: 1–3 daily injections to mimic natural GH pulse patterns
  • Dose Range: 200–300 mcg per injection (combined dose)
  • Cycle Length: Commonly used for 8–12 weeks, depending on goals
  • Dosing Protocol

Suggested approach for the 10 mg combined vial format.

  • Start: 100–200 mcg once daily (preferably before bed) to assess tolerance
  • Target: 200–300 mcg per dose, 1–3 times daily
  • Frequency: Morning (fasted), post-workout, and/or before sleep
  • Vial Duration: One 10 mg vial lasts approximately 10–25 days, depending on dosing frequency
  • Timing: Best used on an empty stomach; avoid food 30–60 minutes before and after injection
  • Mechanism of Action

CJC-1295 (without DAC) is a modified growth hormone–releasing hormone (GHRH) analog that stimulates the pituitary gland to release growth hormone in a pulsatile manner. Unlike the DAC version, it has a shorter half-life, allowing better control over GH pulses.

Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that further enhances GH release without significantly increasing cortisol or prolactin levels. When combined, these peptides create a synergistic effect amplifying natural GH secretion while maintaining physiological rhythm.

This increase in GH may lead to elevated IGF-1 levels, supporting muscle growth, fat metabolism, tissue repair, and improved sleep quality.

  • Potential Benefits & Side Effects

Observations based on preclinical and early-stage research.

Potential Benefits:

  • May increase natural growth hormone and IGF-1 levels
  • May support lean muscle growth and fat loss
  • May improve sleep quality and recovery
  • May enhance skin, hair, and overall tissue repair

Possible Side Effects:

  • Mild water retention
  • Temporary flushing or dizziness
  • Injection-site irritation
  • Increased hunger (less common with Ipamorelin compared to other GHRPs)
  • Long-term human safety data are limited; it remains investigational